NASDAQ:BYSI - Beyondspring News Headlines

Sign in or create an account to add this stock to your watchlist.
$20.40 +0.20 (+0.99 %)
(As of 12/16/2018 01:42 PM ET)
Previous Close$20.40
Today's Range$20.11 - $20.70
52-Week Range$16.15 - $34.00
Volume13,583 shs
Average Volume5,842 shs
Market Capitalization$457.69 million
P/E Ratio-4.64
Dividend YieldN/A
Beta1.33

Headlines

Beyondspring (NASDAQ BYSI) News Headlines

Source:
DateHeadline
BeyondSprings lead candidate on par with Amgens Neulasta in late-stage study; shares ahead 3%BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%
seekingalpha.com - December 6 at 3:59 PM
Beyondspring (BYSI) Given a $60.00 Price Target at HC WainwrightBeyondspring (BYSI) Given a $60.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 6 at 1:29 PM
BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim AnalysisBeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
finance.yahoo.com - December 6 at 10:07 AM
Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSFData for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF
finance.yahoo.com - December 4 at 4:00 PM
Beyondspring Inc (BYSI) Expected to Post Earnings of -$0.55 Per ShareBeyondspring Inc (BYSI) Expected to Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 1 at 7:08 PM
Can The Uptrend Continue for BeyondSpring (BYSI)?Can The Uptrend Continue for BeyondSpring (BYSI)?
finance.yahoo.com - November 30 at 11:10 AM
BeyondSpring (BYSI) Says Plinabulin Newly Granted Patent Covering Method of Use in Prevention of NeutropeniaBeyondSpring (BYSI) Says Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
www.streetinsider.com - November 27 at 3:49 PM
Plinabulin Newly Granted Patent Covering Method of Use in Prevention of NeutropeniaPlinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
finance.yahoo.com - November 27 at 10:58 AM
BeyondSpring up 17% on positive plinabulin dataBeyondSpring up 17% on positive plinabulin data
seekingalpha.com - November 9 at 3:52 PM
Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®
finance.yahoo.com - November 8 at 10:18 AM
BeyondSprings Plinabulin shows positive effect in preventing chemo-induced neutropeniaBeyondSpring's Plinabulin shows positive effect in preventing chemo-induced neutropenia
seekingalpha.com - October 23 at 3:46 PM
BeyondSpring Inc. (BYSI) CEO Lan Huang on Clinical Update Conference Call TranscriptBeyondSpring Inc. (BYSI) CEO Lan Huang on Clinical Update Conference Call Transcript
seekingalpha.com - October 23 at 3:46 PM
BeyondSpring (BYSI) Announces Efficacy and Safety Data from Phase 2 Study 106 with Plinabulin for CIN PreventionBeyondSpring (BYSI) Announces Efficacy and Safety Data from Phase 2 Study 106 with Plinabulin for CIN Prevention
www.streetinsider.com - October 23 at 10:10 AM
BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor MicroenvironmentBeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment
finance.yahoo.com - October 23 at 10:10 AM
BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia PreventionBeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention
finance.yahoo.com - October 23 at 10:10 AM
Beyondspring Provides Operational Update and Second-Quarter 2018 Financial ResultsBeyondspring Provides Operational Update and Second-Quarter 2018 Financial Results
finance.yahoo.com - October 23 at 10:10 AM
BeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSFBeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSF
finance.yahoo.com - October 16 at 10:03 AM
Who Really Owns BeyondSpring Inc (NASDAQ:BYSI)?Who Really Owns BeyondSpring Inc (NASDAQ:BYSI)?
finance.yahoo.com - October 5 at 3:45 PM
Study Opens of BeyondSpring’s Lead Asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung CancerStudy Opens of BeyondSpring’s Lead Asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung Cancer
finance.yahoo.com - October 4 at 9:44 AM
BeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific ConferencesBeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific Conferences
finance.yahoo.com - October 3 at 9:57 AM
BeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for NeutropeniaBeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for Neutropenia
finance.yahoo.com - September 25 at 10:04 AM
BeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for PlinabulinBeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for Plinabulin
finance.yahoo.com - September 19 at 10:15 AM
BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 TrialBeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
finance.yahoo.com - September 6 at 10:40 AM
BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung CancerBeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung Cancer
finance.yahoo.com - August 15 at 10:21 AM
BeyondSpring Sees Hammer Chart Pattern: Time to Buy?BeyondSpring Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - August 7 at 10:33 AM
BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to CommercializationBeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization
finance.yahoo.com - August 1 at 12:14 PM
BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical OncologistsBeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists
finance.yahoo.com - June 25 at 12:17 PM
BeyondSpring, Inc. (BYSI) Q1 2018 Earnings Conference Call TranscriptBeyondSpring, Inc. (BYSI) Q1 2018 Earnings Conference Call Transcript
www.msn.com - June 22 at 12:12 PM
BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial ResultsBeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results
finance.yahoo.com - June 21 at 12:00 PM
BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018
finance.yahoo.com - June 18 at 12:48 PM
BeyondSpring to Present at Upcoming ConferencesBeyondSpring to Present at Upcoming Conferences
finance.yahoo.com - May 31 at 10:42 AM
BeyondSpring commences direct stock offering at $27.06BeyondSpring commences direct stock offering at $27.06
seekingalpha.com - May 30 at 3:46 PM
BeyondSpring Announces $20 Million Registered Direct OfferingBeyondSpring Announces $20 Million Registered Direct Offering
finance.yahoo.com - May 30 at 10:27 AM
BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual MeetingBeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
finance.yahoo.com - May 17 at 10:44 AM
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - May 15 at 11:08 AM
BRIEF-BeyondSpring Says May Offer And Sell Up To 5 Mln Of Cos Ordinary Share From Time to TimeBRIEF-BeyondSpring Says May Offer And Sell Up To 5 Mln Of Co's Ordinary Share From Time to Time
www.reuters.com - April 26 at 10:09 AM
BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual MeetingBeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting
finance.yahoo.com - April 26 at 10:09 AM
BeyondSpring CEO Reveals Novel Tumor TherapyBeyondSpring CEO Reveals Novel Tumor Therapy
finance.yahoo.com - April 25 at 3:49 PM
BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced NeutropeniaBeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
finance.yahoo.com - April 17 at 10:47 AM
Why BeyondSpring (BYSI) Could Be a Potential WinnerWhy BeyondSpring (BYSI) Could Be a Potential Winner
finance.yahoo.com - April 12 at 11:27 AM
BeyondSprings (BYSI) CEO Lan Huang on Q4 2017 Results - Earnings Call TranscriptBeyondSpring's (BYSI) CEO Lan Huang on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - April 5 at 8:54 AM
BeyondSpring Files Its 2017 Annual Report on Form 20-FBeyondSpring Files Its 2017 Annual Report on Form 20-F
finance.yahoo.com - April 4 at 5:11 PM
BRIEF-Beyondspring Qtrly Loss Per Share $0.68BRIEF-Beyondspring Qtrly Loss Per Share $0.68
www.reuters.com - April 3 at 10:49 AM
BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial ResultsBeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - April 3 at 10:49 AM
BeyondSpring appoints Edward Dongheng Liu as CFOBeyondSpring appoints Edward Dongheng Liu as CFO
seekingalpha.com - March 28 at 10:41 AM
BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018
finance.yahoo.com - March 28 at 10:41 AM
BRIEF-Beyondspring Says, Co Appointed Edward Dongheng Liu As Its Chief Financial Officer, Effective ImmediatelyBRIEF-Beyondspring Says, Co Appointed Edward Dongheng Liu As Its Chief Financial Officer, Effective Immediately
www.reuters.com - March 27 at 10:53 AM
BeyondSpring Appoints Edward Dongheng Liu as Chief Financial OfficerBeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer
finance.yahoo.com - March 27 at 10:53 AM
BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced NeutropeniaBeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
finance.yahoo.com - March 19 at 10:39 AM
BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018
finance.yahoo.com - March 15 at 10:40 AM
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: Intrinsic Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel